JP2025503614A5 - - Google Patents

Info

Publication number
JP2025503614A5
JP2025503614A5 JP2024540897A JP2024540897A JP2025503614A5 JP 2025503614 A5 JP2025503614 A5 JP 2025503614A5 JP 2024540897 A JP2024540897 A JP 2024540897A JP 2024540897 A JP2024540897 A JP 2024540897A JP 2025503614 A5 JP2025503614 A5 JP 2025503614A5
Authority
JP
Japan
Application number
JP2024540897A
Other languages
Japanese (ja)
Other versions
JP2025503614A (ja
JPWO2023133486A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/060207 external-priority patent/WO2023133486A2/en
Publication of JP2025503614A publication Critical patent/JP2025503614A/ja
Publication of JP2025503614A5 publication Critical patent/JP2025503614A5/ja
Publication of JPWO2023133486A5 publication Critical patent/JPWO2023133486A5/ja
Pending legal-status Critical Current

Links

JP2024540897A 2022-01-07 2023-01-06 甲状腺眼疾患を治療するための組成物及び方法 Pending JP2025503614A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263266549P 2022-01-07 2022-01-07
US63/266,549 2022-01-07
PCT/US2023/060207 WO2023133486A2 (en) 2022-01-07 2023-01-06 Compositions and methods for treatment of thyroid eye disease

Publications (3)

Publication Number Publication Date
JP2025503614A JP2025503614A (ja) 2025-02-04
JP2025503614A5 true JP2025503614A5 (https=) 2026-01-16
JPWO2023133486A5 JPWO2023133486A5 (https=) 2026-01-16

Family

ID=87074299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540897A Pending JP2025503614A (ja) 2022-01-07 2023-01-06 甲状腺眼疾患を治療するための組成物及び方法

Country Status (9)

Country Link
US (1) US20240343814A1 (https=)
EP (1) EP4460525A4 (https=)
JP (1) JP2025503614A (https=)
KR (1) KR20240141213A (https=)
CN (1) CN118974086A (https=)
AU (1) AU2023205789A1 (https=)
CA (1) CA3242661A1 (https=)
MX (1) MX2024008529A (https=)
WO (1) WO2023133486A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119792512A (zh) 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
WO2025014774A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating active and chronic thyroid eye disease
WO2025106642A1 (en) * 2023-11-14 2025-05-22 Tourmaline Bio, Inc. Methods for the treatment of thyroid eye disease
WO2025136985A1 (en) * 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN113402602B (zh) * 2020-03-17 2022-09-23 上海祥耀生物科技有限责任公司 一种新型冠状病毒SARS-CoV-2中和性抗体及应用

Similar Documents

Publication Publication Date Title
JP2025503614A5 (https=)
CL2025003690A1 (es) Compuestos anti-vih.
CL2025003148A1 (es) Proceso y aparato para preparar trióxido de azufre a partir de dióxido de azufre
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307044498S (https=)
CN307046743S (https=)
BY13176U (https=)
BY23969C1 (https=)
BY23993C1 (https=)
CN307044233S (https=)
BY13144U (https=)